CRBN and neoplasm: Moreover, the absence of CRBN mutations in all publicly accessible tumor samples from SCLC patients—a major subgroup of NE cancers—further supports the notion that this patient population may be largely free from resistance mechanisms associated with CRBN mutations (Supplementary Figure S10B).